Shares of Noveris Health Sciences (CSE: NVRS) plunged 20.8% to C$1.90 on June 12 after the Vancouver-based biotech announced Nathan Mison — a cannabis-industry lobbyist and government-affairs consultant — as Chair of its Advisory Board. The move arrives with no accompanying clinical or financial milestone, leaving investors to question what, exactly, they are paying for.
A Rebranded Shell Still Searching for a Business
Noveris was formerly known as Mydecine Innovations Group and changed its name in February 2026.
Prior to its recent recapitalization, the company was focused primarily on debt restructuring and its other active operations had been paused due to a lack of funding.
Noveris is a pre-revenue company with no products that have received regulatory approval.
Its research and development activities are currently paused, meaning shareholders own little more than a patent portfolio and cash from a recent financing.
A Troubled Track Record of Volatility and Regulatory Scrutiny
The British Columbia Securities Commission issued an order in March 2026 halting all trading in the company's securities until April 16 due to "unexplained and unusual fluctuations in the volume of trading in, or market price, of the Company's shares."
Shareholders have been substantially diluted in the past year, with over a 38× increase in shares outstanding — meaning each share's claim on future earnings has been slashed dramatically.
The New Adviser's Background Raises More Questions Than Answers
Mison is President and Founding Partner of Diplomat Consulting, a regulatory-affairs firm. He is co-chair of the National Cannabis Working Group for the Canadian Chamber of Commerce and a member of the Business Industry Advisory Council for the OECD. His résumé is heavy on government relations and cannabis policy — not drug development or clinical science. For a company whose stated mission centers on psilocybin-based mental-health therapies, the hire signals a pivot toward lobbying and deal-making rather than lab work.
No Revenue, No Pipeline Progress, and a Stock That Keeps Whipsawing The price swung from C$2.86 on June 5 to C$2.95 on June 8, retreated to C$2.18 on June 9, then rebounded to C$2.40 before today's collapse. Total loss to shareholders over the past three years stands at 90%. Until Noveris shows concrete clinical progress or a credible acquisition target, each new advisory appointment looks less like strategy and more like stage dressing for a company whose science remains on ice.